Skip to main content
SpringerLink
Log in

Apixaban for prevention of thromboembolic complications in non-valvular AF: better outcomes, lower cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Pfizer and Bristol Myers Squibb.

Reference

  • Hallinen T, et al. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. ClinicoEconomics and Outcomes Research : 13 Aug 2021. Available from: URL: https://doi.org/10.2147/CEOR.S317078

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban for prevention of thromboembolic complications in non-valvular AF: better outcomes, lower cost. PharmacoEcon Outcomes News 887, 4 (2021). https://doi.org/10.1007/s40274-021-08020-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08020-2

Search

Navigation